Nature Communications (Jun 2016)
A broad analysis of resistance development in the malaria parasite
- Victoria C. Corey,
- Amanda K. Lukens,
- Eva S. Istvan,
- Marcus C. S. Lee,
- Virginia Franco,
- Pamela Magistrado,
- Olivia Coburn-Flynn,
- Tomoyo Sakata-Kato,
- Olivia Fuchs,
- Nina F. Gnädig,
- Greg Goldgof,
- Maria Linares,
- Maria G. Gomez-Lorenzo,
- Cristina De Cózar,
- Maria Jose Lafuente-Monasterio,
- Sara Prats,
- Stephan Meister,
- Olga Tanaseichuk,
- Melanie Wree,
- Yingyao Zhou,
- Paul A. Willis,
- Francisco-Javier Gamo,
- Daniel E. Goldberg,
- David A. Fidock,
- Dyann F. Wirth,
- Elizabeth A. Winzeler
Affiliations
- Victoria C. Corey
- Department of Pediatrics, School of Medicine, University of California San Diego
- Amanda K. Lukens
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health
- Eva S. Istvan
- Department of Medicine and Microbiology, Washington University School of Medicine
- Marcus C. S. Lee
- Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons
- Virginia Franco
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline
- Pamela Magistrado
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health
- Olivia Coburn-Flynn
- Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons
- Tomoyo Sakata-Kato
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health
- Olivia Fuchs
- Department of Pediatrics, School of Medicine, University of California San Diego
- Nina F. Gnädig
- Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons
- Greg Goldgof
- Department of Pediatrics, School of Medicine, University of California San Diego
- Maria Linares
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline
- Maria G. Gomez-Lorenzo
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline
- Cristina De Cózar
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline
- Maria Jose Lafuente-Monasterio
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline
- Sara Prats
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline
- Stephan Meister
- Department of Pediatrics, School of Medicine, University of California San Diego
- Olga Tanaseichuk
- The Genomics Institute of the Novartis Research Foundation
- Melanie Wree
- Department of Pediatrics, School of Medicine, University of California San Diego
- Yingyao Zhou
- The Genomics Institute of the Novartis Research Foundation
- Paul A. Willis
- Medicines for Malaria Venture
- Francisco-Javier Gamo
- Tres Cantos Medicines Development Campus, Malaria DPU, GlaxoSmithKline
- Daniel E. Goldberg
- Department of Medicine and Microbiology, Washington University School of Medicine
- David A. Fidock
- Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons
- Dyann F. Wirth
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health
- Elizabeth A. Winzeler
- Department of Pediatrics, School of Medicine, University of California San Diego
- DOI
- https://doi.org/10.1038/ncomms11901
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 9
Abstract
It is unclear whether new antimalarial compounds may rapidly lose effectiveness in the field because of parasite resistance. Here, Corey et al.investigate the acquisition of drug resistance and the extent to which common resistance mechanisms decrease susceptibility to a diverse set of 50 antimalarial compounds.
